Here is a business idea that sounds either obvious or slightly insane, depending on how you feel about your own mortality. You take a healthy person - someone with no complaints, no symptoms, a clean bill of health from their regular doctor - and you sequence their entire genome, run them through a whole-body MRI, draw hundreds of blood biomarkers, and feed all of it to a machine-learning model. Then you look, very hard, for the thing that is quietly wrong. Sometimes you find it. Often you don't, and the person pays several thousand dollars to be told they are fine, which turns out to be a product people will happily buy.
This is, more or less, Human Longevity, Inc. The company was founded in 2013 by J. Craig Venter - the geneticist who helped produce one of the first draft sequences of the human genome and later built a cell run by a synthetic chromosome - along with entrepreneur Peter Diamandis and physician-scientist Robert Hariri. The founding premise was that the genome, on its own, is a map with no legend. You need the phenotype too: the imaging, the metabolites, the years of follow-up. Collect enough genotype-and-phenotype pairs, the theory went, and machine learning could start telling you which genetic variants actually mattered.
The Product Is a Day
The place where all of this happens is called Health Nucleus, launched in 2015. The idea is elegant in the way that expensive things often are: you show up, and over roughly a single day you get whole genome sequencing, a full-body MRI, hundreds of laboratory biomarkers, and continuous cardiac monitoring, and then an AI-assisted analysis stitches it together into a risk picture. The pitch is not that you are sick. The pitch is that if you are going to become sick, the earliest evidence probably already exists somewhere in that data, and it is cheaper - in every sense - to find it now.
The company has run this assessment on more than 10,000 people. The demographics are what you would guess. The average client is around 53. They skew toward executives, technologists, and investors - people for whom a data-driven approach to their own body feels natural, and for whom the bill, often paid by an employer, is a rounding error. Membership tiers have ranged from roughly $4,950 for an entry point to $25,000 for the platinum version, with a popular middle option around $12,000 that buys two assessments a year.
The Unicorn That Lost Its Horn
Now, a company built on sequencing and MRI machines is a capital-intensive thing, and Human Longevity raised accordingly. There was an $80 million Series A in 2014, then a $220 million Series B in 2016 with Illumina, Celgene, and GE Ventures - a genuinely large private round for genomics at the time. By 2017 the company was valued at more than $1.6 billion, which made it a unicorn, which is the sort of thing that generates magazine profiles.
Then the horn came off. The valuation fell roughly 80 percent, to around $310 million, amid executive turnover that reads like a revolving door: a CEO hired from GE Healthcare and gone within a year, a chief medical officer departing, and eventually Venter himself stepping back toward his namesake research institute. In late 2019 the company raised a comparatively modest $30 million, and Wei-Wu He took over as executive chairman. A proposed 2022 SPAC listing floated a $1 billion valuation and did not, in the end, produce a public company. This is the part of the story that is easy to be cynical about, and the cynicism is not entirely wrong. But it misses what the company was quietly accumulating the whole time.
The Asset Was Never the Valuation
What Human Longevity was building, through all the drama, was a dataset. Over a decade it invested more than $600 million collecting and analyzing longitudinal health data - genomes paired with imaging, biomarkers, and years of follow-up - on thousands of individuals. In 2020 the company published a study in the Proceedings of the National Academy of Sciences demonstrating that integrating whole-genome sequencing, imaging, and metabolomics could surface health risks that any one test would have missed. That is the whole thesis, validated in a journal: the combination sees what the components cannot.
Datasets like this compound. And in 2026 the company started spending the compound interest. It launched a clinical-grade whole genome sequencing report for $599 - a startling drop from the era when a comparable genome-plus-imaging workup could run $50,000 - explicitly framed as a way to bring genomic medicine to the general population, and dedicated to Venter, who died that year at 79. In the same stretch it spun out a new entity, Human Life Foundation Models, Inc., to build large-scale AI foundation models for longevity science, with a multi-year collaboration with the AI-drug-discovery firm Insilico Medicine as its first partnership.
What You Can Actually Do With It
Stripped of the valuation theater, the offer to a person is straightforward. If you want the full experience, you can book an executive health assessment and spend a day getting mapped in more detail than almost any clinical setting will provide. If you want the entry point, you can now buy a clinical-grade read of your own genome for $599 and get AI-generated insights about inherited risk. In both cases the promise is the same one the company started with: not a cure, not a guarantee, but earlier information. Whether earlier information makes you healthier - as opposed to more anxious, or chasing incidental findings - is a real and unsettled debate in screening medicine. Human Longevity's bet, across thirteen years and one very bumpy valuation chart, is that on balance it does.